Inozyme Pharma (INZY) Stock Forecast & Price Target

$5.17

+0.11 (+2.17%)

(As of 10/4/2024 ET)

Inozyme Pharma - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 7 Analyst Ratings

Sell
0

Hold
0

Buy
7

Based on 7 Wall Street analysts who have issued ratings for Inozyme Pharma in the last 12 months, the stock has a consensus rating of "Buy." Out of the 7 analysts, 7 have given a buy rating for INZY.

Consensus Price Target

$16.14
212.24% Upside

According to the 7 analysts' twelve-month price targets for Inozyme Pharma, the average price target is $16.14. The highest price target for INZY is $23.00, while the lowest price target for INZY is $14.00. The average price target represents a forecasted upside of 212.24% from the current price of $5.17.

Get the Latest News and Ratings for INZY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Inozyme Pharma and its competitors.

INZY Analyst Ratings Over Time

Type	Current Forecast 10/7/23 to 10/6/24	1 Month Ago 9/7/23 to 9/6/24	3 Months Ago 7/9/23 to 7/8/24	1 Year Ago 10/7/22 to 10/7/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	6 Buy rating(s)	5 Buy rating(s)	4 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$16.14	$16.17	$16.00	$15.00
Forecasted Upside	212.24% Upside	224.63% Upside	247.83% Upside	288.60% Upside
Consensus Rating	Buy	Buy	Buy	Buy

How a $200,000 Mistake Unlocked a $118 Billion Gold Treasure (Ad)

The window of opportunity on this gold stock is closing fast. Once word gets out, it may be too late.

Click here now to learn how you can position yourself for potentially massive gains.

INZY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

INZY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Inozyme Pharma Stock vs. The Competition

Type	Inozyme Pharma	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.79	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	212.24% Upside	10,590.90% Upside	7.05% Upside
News Sentiment Rating	Positive News See Recent INZY News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
9/30/2024	Wedbush 3 of 5 stars	Reiterated Rating	Outperform ➝ Outperform	$15.00 ➝ $15.00	+189.57%
9/12/2024	Stifel Nicolaus 4 of 5 stars	Initiated Coverage	Buy	$16.00	+207.10%
8/13/2024	Jefferies Financial Group 2 of 5 stars	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $17.00	+291.70%
8/8/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00	+224.83%
8/6/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00	+377.18%
5/30/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$14.00	+210.42%
Get the Latest News and Ratings for INZY and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter.
4/9/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$16.00 ➝ $14.00	+164.15%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 12:07 PM ET.

INZY Forecast - Frequently Asked Questions

: According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Inozyme Pharma is $16.14, with a high forecast of $23.00 and a low forecast of $14.00.
: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inozyme Pharma in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" INZY shares.
: According to analysts, Inozyme Pharma's stock has a predicted upside of 212.24% based on their 12-month stock forecasts.
: Inozyme Pharma has been rated by research analysts at HC Wainwright, Jefferies Financial Group, Needham & Company LLC, Stifel Nicolaus, and Wedbush in the past 90 days.
: Analysts like Inozyme Pharma more than other "medical" companies. The consensus rating for Inozyme Pharma is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how INZY compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Retire off just one stock ticker? (Ad)

ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT make you rich. However, there is one stock that stands head and shoulders above everything else. It's currently trading for only $15...

Click here for the ticker >>>

This page (NASDAQ:INZY) was last updated on 10/6/2024 by MarketBeat.com Staff

From Our Partners